The prevalence of HIV resistance mutations and their influence on the shedding of HIV‐1 into peritoneal dialysis effluent

Abstract

AbstractHIV drug resistance mutations (HIVDRMs) are important determinants of therapeutic effects and outcomes even in end‐stage kidney failure (ESKF) people living with HIV (PLWHIV). This study evaluated the prevalence of HIVDRMs and their effect on the shedding of HIV‐1 into peritoneal dialysis (PD) effluents. This cross‐sectional study of PLWHIV and having ESKF and managed with antiretroviral therapy (ART) and PD, collected enrolled patients’ demographic information, clinical and laboratory data, and sequenced HIV‐1 RNA in unsuppressed plasma and PD effluent samples. HIV viral load and HIVDRMs were determined using qualitative polymerase chain reaction (qPCR) and Stanford University HIVDRM Database, respectively. There were 60 participants recruited with a median age of 43.0 (interquartile range [IQR], 38.0–47) years and were predominantly on abacavir (88.3%), lamivudine (98.3%), and efavirenz (70%) for a median duration of 8 (IQR, 5–11) years. Among participants with detectable HIV‐1 in PD effluents, the prevalence of HIVDRMs was 62.5% (5/8) compared to 7.7% (4/52) among those with undetectable HIV‐1 (p = 0.001) with non‐nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations predominating. On Spearman's correlation analysis, high plasma HIV levels (ρ = 0.649, p < 0.001), T‐cell CD4 count (ρ = −0370, p < 0.004), serum creatinine (ρ = −0.396, p < 0.002), and white blood cell count (ρ = −0.294, p < 0.023) levels were significant factors correlated with the detection of HIV‐1 in PD effluents. Moreover, HIVDRMs presence (ρ = 0.504, p < 0.001) particularly NNRTI resistance (ρ = 0.504, p < 0.001) were also significantly correlated with detection of HIV‐1 in PD effluents. The presence of HIVDRMs, high plasma HIV viral load, and T‐cell CD4 count were correlated with HIV‐1 shedding into PD effluents.